Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
Hill

Senate bill S. 5812 would permanently extend HHS authority to award priority review vouchers for rare pediatric disease products, and was referred to the HELP Committee on 2026-11-19.

Why it’s here: A federal bill extending FDA priority review vouchers for rare pediatric disease products is direct federal policy on biotechnology regulation and innovation incentives, squarely within the Biotechnology area despite the source's energy specialty.

Trace across the board

Item

Connected

5 links

About

  • Senate Committee on Health, Education, Labor, and Pensions (HELP)
  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

Senate bill S. 5812 would permanently extend HHS authority to award priority review vouchers for rare pediatric disease products, and was referred to the HELP Committee on 2026-11-19. — The Wave